Company intelligence / Profile preview

4401 Santa Anita

El Monte, California, United States

Ownership: Private
Employees: ~750
Development stage: Other

Overview

Fulgent Genetics is a genomics and diagnostics leader with expanding oncology therapeutics through their proprietary nano-drug delivery platform. FID-007 is in Phase 2 for head & neck cancer; FID-022 (nanoencapsulated SN-38) IND cleared for several cancers.

Therapeutic areas: Oncology
Modalities: Small moleculeAntibody-drug conjugateNanoparticle(Platform technology enables multiple modalities)
Industry: Biotech

Partnerships

Strategic supplier partnership with Illumina (sequencing systems)industry labspharmaceutical/biotech partners for contract testing

Beyond the preview

Go deeper on 4401 Santa Anita.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 4401 Santa Anita.

Explore the full profile